MARKET

EVFM

EVFM

Evofem Bioscienc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3494
+0.0024
+0.69%
After Hours: 0.3500 +0.0006 +0.17% 19:59 05/27 EDT
OPEN
0.3500
PREV CLOSE
0.3470
HIGH
0.3570
LOW
0.3416
VOLUME
2.29M
TURNOVER
0
52 WEEK HIGH
21.30
52 WEEK LOW
0.3350
MARKET CAP
5.13M
P/E (TTM)
-0.0184
1D
5D
1M
3M
1Y
5Y
--Piper Sandler Adjusts Price Target on Evofem Biosciences to $2 From $30, Reiterates Overweight Rating
MT Newswires · 3d ago
66 Biggest Movers From Friday
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.
Benzinga · 5d ago
Mid-Afternoon Market Update: Dow Dips Over 500 Points; Ross Stores Shares Slide
U.S. stocks extended losses toward the end of trading, with the Dow Jones dropping more than 500 points on Friday.
Benzinga · 05/20 18:36
NNVC, BEST and PYR among mid-day movers
Gainers: Leju Holdings Limited (LEJU) +47%. Redbox Entertainment (RDBX) +33%. SIGA Technologies (SIGA) +26%. Getnet (GET) +25%. Allarity (ALLR) +23%. NanoViricides (NNVC) +22%. Processa Pharmaceuticals (PCSA) +22%. TherapeuticsMD (TXMD) +17%.
Seekingalpha · 05/20 16:37
Mid-Day Market Update: Dow Tumbles 200 Points; TherapeuticsMD Shares Jump
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 200 points on Friday.
Benzinga · 05/20 16:03
Sector Update: Health Care
MT Newswires · 05/20 15:58
Why Evofem Biosciences Shares Are Getting Hammered Today
Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading lower by 59.76% at $0.44 after the company announced the pricing of a roughly $26.6 million public offering.
Benzinga · 05/20 14:50
Immix Biopharma, MDxHealth top healthcare gainers; Evofem, Bright Green lead losers' pack
Gainers: Immix Biopharma (IMMX) +48%. MDxHealth (MDXH) +31%. ClearPoint Neuro (CLPT) +16%. Covetrus (CVET) +14%. Kronos Bio (KRON) +13%. Losers: Evofem Biosciences (EVFM) -58%. Bright Green (BGXX) -26%. Foghorn Therapeutics (FHTX) -19%. NeuroMetrix (NURO) ...
Seekingalpha · 05/20 14:07
More
No Data
Learn about the latest financial forecast of EVFM. Analyze the recent business situations of Evofem Bioscienc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
50.00%Buy
0.00%Hold
25.00%Under-perform
0.00%Sell
Analyst Price Target
The average EVFM stock price target is 26.75 with a high estimate of 45.00 and a low estimate of 2.000.
High45.00
Average26.75
Low2.000
Current 0.3494
EPS
Actual
Estimate
-5.88-4.56-3.25-1.93
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 150
Institutional Holdings: 23.16M
% Owned: 182.15%
Shares Outstanding: 14.68M
TypeInstitutionsShares
Increased
15
243.51K
New
11
10.26K
Decreased
17
229.91K
Sold Out
5
259.68K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
President/Chief Executive Officer/Director
Saundra Pelletier
Chief Financial Officer
Justin File
Executive Vice President/General Counsel/Secretary
Alexander Fitzpatrick
Independent Director
Gillian Greer
Independent Director
Kim Kamdar
Independent Director
Tony O'Brien
Independent Director
Lisa Rarick
Independent Director
Colin Rutherford
No Data
No Data
About EVFM
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and commercializing products to address needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from sexually transmitted infections (STIs). The Company's product, Phexxi vaginal gel, is an on-demand prescription contraceptive gel for women. Its pipeline product candidate, EVO100 vaginal gel, is evaluated for the prevention of chlamydia trachomatis infection and Neisseria gonorrhoeae in women. The Company also focuses on the development of EVO200 vaginal gel, its candidate for the reduction of recurrent bacterial vaginosis (BV).Its subsidiaries include Evofem Biosciences Operations Inc, Evofem Inc and Evofem Ltd.

Webull offers kinds of Evofem Biosciences Inc stock information, including NASDAQ:EVFM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVFM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVFM stock methods without spending real money on the virtual paper trading platform.